Quetiapine monotherapy for bipolar depression

Philip G. Janicak, Jeffrey T. Rado

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Introduction: Depression, in the context of bipolar disorder, is more prevalent than hypomania or mania and accounts for most of the disability. Furthermore, the treatment of bipolar depression is more complicated than the treatment of unipolar major depression. Finally, the evidence base for pharmacotherapy of bipolar depression is much smaller than for unipolar depression or hypomania/mania. Areas covered: The article examines the mechanism of action and pharmacokinetics of quetiapine, its evidence base as a treatment for bipolar depression and related issues of safety and tolerability. Expert opinion: In the context of bipolar disorder, quetiapine is the only monotherapy approved for the treatment of hypomania/mania, depression and as an adjunctive maintenance therapy. In addition to its antipsychotic properties, this broad mood stabilizing potential may uniquely benefit and simplify the management of some bipolar patients who can tolerate this agent.

Original languageEnglish (US)
Pages (from-to)1643-1651
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number10
StatePublished - Jul 2011


  • bipolar depression
  • monotherapy
  • quetiapine
  • second generation antipsychotic

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Quetiapine monotherapy for bipolar depression'. Together they form a unique fingerprint.

Cite this